Human Papillomavirus (HPV) and Oncogenic Viruses
Some viruses can cause cancer. Human papillomavirus (HPV) causes cervical and several other cancers, hepatitis B and C cause liver cancer, and Epstein–Barr virus is linked to nasopharyngeal cancer and lymphoma, which are important in Asia.
The Human Papillomavirus (HPV) and Oncogenic Viruses session at Infectious 2027 covers virus-related cancers and their prevention. It connects closely with STD and HIV infection, as HPV is sexually transmitted.
Some long-lasting viral infections can slowly cause changes that lead to cancer. Vaccines, screening and antiviral treatment can stop this process. HPV and hepatitis B vaccines are among the most powerful cancer prevention tools available. Many virus-related cancers are common in Asia.
Key Topics in Human Papillomavirus (HPV) and Oncogenic Viruses
• HPV infection and cervical cancer
• HPV vaccination programmes
• HPV screening and self-sampling
• Hepatitis B and C and liver cancer
• Epstein–Barr virus and related cancers
• HTLV-1 and Kaposi sarcoma herpesvirus
• Mechanisms of viral oncogenesis
• Oropharyngeal and anal HPV cancers
• Cervical cancer elimination strategies
• Oncogenic viruses in people with HIV
Recent Advances in Human Papillomavirus (HPV) and Oncogenic Viruses
HPV vaccination is leading to large falls in cervical pre-cancer, and single-dose schedules are making programmes easier to run. Self-sampling HPV tests, linked with diagnostic innovations in infectious diseases, are reaching more women.
Research on how viruses cause cancer, part of molecular biology and genomics, is revealing new treatment targets. Vaccine coverage and equity, discussed in vaccine development and immunization, are key to cervical cancer elimination.
Single-dose HPV vaccination is making programmes easier to deliver. Self-collected HPV tests are reaching women who do not attend screening. Antiviral treatment for hepatitis B and C is lowering liver cancer risk. Research on Epstein-Barr virus is improving early detection of nasopharyngeal cancer.
Who Should Attend the Human Papillomavirus (HPV) and Oncogenic Viruses Session
• Infectious disease and oncology specialists
• Gynaecologists and hepatologists
• Virologists and cancer researchers
• Screening and immunisation programme staff
• PhD students and early-career researchers
• Public health professionals
Why Present Your Research in Human Papillomavirus (HPV) and Oncogenic Viruses
Presenting at Infectious 2027 lets you share research on virus-related cancers with an international audience. You can connect with colleagues in infectious diseases and public health working on screening and prevention. This session links infection and cancer specialists. Sharing your work here supports prevention programmes worldwide.
Frequently Asked Questions
Does this session cover hepatitis B and liver cancer?
Yes. Hepatitis viruses and liver cancer fit this session.
Can I present HPV vaccination programme data?
Yes. Vaccination programme studies are welcome.
Where is Infectious 2027?
Infectious 2027 is held at Village Hotel Changi, Singapore, from 11 to 13 March 2027, with online participation.